My HappyStock
Log in to track your learning progress.
US Companies
Find my preferred stocks →Compare companies across six criteria and explore businesses that fit your priorities.
JNJ
Johnson & Johnson (JNJ)
Average score 7.6 B
Preference —
Six company scores
Average score
Company growth7 / 10
Oncology drugs and new launches support sales growth
Profitability9 / 10
Patented medicines and devices sustain strong margins
Financial stability8 / 10
Solid cash flow; litigation remains a financial risk
Economic moat10 / 10
Patents, regulatory hurdles and physician trust deter rivals
Future outlook8 / 10
New cancer drugs and robotics grow; patent cliffs loom
Valuation4 / 10
Premium forward P/E reflects high expectations
Editorial scores are for education, not audited financial metrics or investment advice.
Revenue by business
- Innovative Medicine 65.98%
Oncology, immunology, neuroscience and other medicines
- MedTech 34.02%
Cardiovascular, surgical, orthopaedic and vision devices
Revenue by region
- United States 58.9%
- Europe 21.28%
- Western Hemisphere ex-U.S. 5.45%
- Asia-Pacific & Africa 14.37%
Key metrics
| Revenue CAGR (5 years) | 7% |
|---|---|
| Operating income CAGR (5 years) | - |
| Net income CAGR (5 years) | - |
| Operating margin (5-year avg.) | 27% |
| ROE (5-year avg.) | 24% |
| ROA (5-year avg.) | 8% |
| Beta (5 years) | 0.2 |
| MDD (5 years) | -24% |
| Payout ratio (5-year avg.) | 56% |
| P/E | 43x |
| Forward P/E | 25x |
| PEG | 3.44 |